CEACAM19: A Carcinoembryonic Antigen-Related Cell Adhesion Molecule 19

Target Name: CEACAM19

NCBI ID: G56971

CEACAM19

CEACAM19: A Carcinoembryonic Antigen-Related Cell Adhesion Molecule 19

Carcinoembryonic antigen (CEA) is a glycoprotein that is expressed in various tissues and organs, including the cancer cells. It is a glycoprotein that is composed of a cell surface protein and a cytoplasmic protein. CEA is known to be a protein that is overexpressed in various types of cancer, including breast, lung, and ovarian cancer.

In addition to its role in cancer, CEA has also been identified as a potential drug target. Researchers have found that CEA can interact with several different proteins, including the cell adhesion molecule 1 (CAM) protein. The CAM protein is a transmembrane protein that is involved in cell-cell adhesion and survival.

CEACAM19: A Putative Drug Target

The Carcinoembryonic Antigen (CEA) gene has been identified as a potential drug target in cancer. Specifically, CEACAM19, a gene that is related to CEA, has been shown to be involved in cell adhesion and survival.

CEACAM19 is a 21-kDa glycoprotein that is expressed in various tissues and organs, including the brain, pancreas, and gastrointestinal tract. It is composed of a cytoplasmic portion and a cell surface portion that is involved in cell adhesion and survival.

Studies have shown that CEACAM19 is involved in several different processes in cancer, including the development and progression of cancer, the regulation of cell adhesion, and the regulation of cell survival. For example, studies have shown that high levels of CEACAM19 are associated with poor prognosis in patients with pancreatic cancer.

In addition to its role in cancer, CEACAM19 has also been identified as a potential biomarker for cancer. This is because it is a protein that is expressed in various tissues and organs, including cancer cells. As such, it is a potential target for cancer therapies that can inhibit its expression or activity.

Targeting CEACAM19: A Potential Strategy

One strategy for targeting CEACAM19 is to use small molecules that can inhibit its expression or activity. This can be done either by inhibiting the activity of CEACAM19 itself or by inhibiting the activity of the proteins that it interacts with, such as CAM proteins.

There are several different small molecules that have been shown to be potential inhibitors of CEACAM19. For example, one small molecule, called compound A, has been shown to inhibit the activity of CEACAM19 and to reduce the amount of CEACAM19 that is expressed in cancer cells.

Another small molecule, called compound B, has also been shown to inhibit the activity of CEACAM19 and to reduce the amount of CEACAM19 that is expressed in cancer cells.

In addition to small molecules, researchers have also shown that targeting CEACAM19 using antibodies is a potential strategy for targeting it. This can be done by using antibodies that recognize and bind to CEACAM19, and then using those antibodies to block its activity.

Conclusion

CEACAM19 is a glycoprotein that is involved in cell adhesion and survival. It has been identified as a potential drug target in cancer, and several small molecules and antibodies have been shown to be potential inhibitors of its expression or activity. Further research is needed to fully understand the role of CEACAM19 in cancer and to develop effective therapies that can target it.

Protein Name: CEA Cell Adhesion Molecule 19

The "CEACAM19 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CEACAM19 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets